CDER’s current proposal to withdraw the accelerated acceptance of Makena (HPC) was centered upon a significant randomized demo that failed to verify the benefit of this drug to newborns or decrease the potential risk of PTB. In creating the choice to propose Makena’s withdrawal, CDER also reviewed benefits from prior scientific studies of pro